PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

Official Title

Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of COVID-19 by lab test within 5 days of study participation
Exclusion Criteria:
  1. - Allergy to "iodine," shellfish, or food dye - Receiving intranasal steroids - Sinus surgery within 30 days of beginning the study - Intubated at the time of enrollment - Pregnancy - Participation in other COVID-19 studies - to be determined on a case by case basis


Jayakar V. Nayak, MD, PhD
Jayakar V. Nayak, MD, PhD
Head and neck surgeon, Rhinologist, Otolaryngologist, Ear, nose, and throat specialist
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.


Peter H Hwang, MD